ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Nicox SA

Nicox SA (ALCOX)

0.302
0.00
(0.00%)
Cerrado 17 Enero 10:30AM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.302
Postura de Compra
0.296
Postura de Venta
0.302
Volume Operado de la Acción
101,343
0.296 Rango del Día 0.302
0.14 Rango de 52 semanas 0.4915
Capitalización de Mercado [m]
Precio Anterior
0.302
Precio de Apertura
0.296
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
145,351
Acciones en circulación
50,299,694
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-13.66
Beneficio por acción (BPA)
-0.42
turnover
7.14M
Beneficio neto
-20.88M

Acerca de Nicox SA

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Antibes, Alpes-maritimes, Fra
Fundado
-
Nicox SA is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALCOX. The last closing price for Nicox was 0.30 €. Over the last year, Nicox shares have traded in a share price range of 0.14 € to 0.4915 €.

Nicox currently has 50,299,694 shares in issue. The market capitalisation of Nicox is 15.19 € million. Nicox has a price to earnings ratio (PE ratio) of -13.66.

ALCOX Últimas noticias

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents

Nicox annonce la première vente commerciale de ZERVIATE en Chine par son partenaire Ocumension, création d’une nouvelle source de revenus récurrents Communiqué de presseNicox annonce la première...

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream Press Release Nicox Announces First Commercial Sale of ZERVIATE in China...

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470

Nicox : Recrutement de patients achevé plus tôt que prévu en Chine dans l’étude clinique de phase 3 Denali sur NCX 470 Communiqué de presseNicox : Recrutement de patients achevé plus tôt que prévu...

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Press ReleaseNicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms...

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470

Nicox annonce la publication de la partie adaptive de l’étude clinique de phase 3 Mont Blanc sur NCX 470 Communiqué de presseNicox annonce la publication de la partie adaptive de l’étude clinique...

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc...

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024

Nicox : Point financier sur le troisième trimestre 2024 et résultats financiers du premier semestre 2024 Communiqué de presseNicox : Point financier sur le troisième trimestre 2024 et résultats...

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results  Topline results from...

Nicox et Soleus signent un accord de financement de 16,5 millions de dollars combinant la vente de redevances et un financement en fonds propres

Nicox et Soleus signent un accord de financement de 16,5 millions de dollars combinant la vente de redevances et un financement en fonds propres Communiqué de presse Nicox et Soleus signent un...

Nicox and Soleus Sign $16.5 million Royalty and Equity Financing

Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.019-5.919003115260.3210.3260.29051165480.30622709DE
40.0082.721088435370.2940.3350.281386460.30800085DE
120.042516.37764932560.25950.3350.20051453510.27782696DE
260.11561.49732620320.1870.3350.142564660.25571256DE
52-0.1135-27.31648616130.41550.49150.141731290.26582941DE
156-0.28-48.10996563570.5820.650.141378390.31864537DE
260-0.28-48.10996563570.5820.650.141378390.31864537DE

ALCOX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Nicox?
El precio actual de las acciones de Nicox es 0.302 €
¿Cuántas acciones de Nicox están en circulación?
Nicox tiene 50,299,694 acciones en circulación
¿Cuál es la capitalización de mercado de Nicox?
La capitalización de mercado de Nicox es EUR 15.19M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Nicox?
Nicox ha negociado en un rango de 0.14 € a 0.4915 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Nicox?
El ratio precio/beneficio de Nicox es -13.66
¿Cuál es el ratio de efectivo a ventas de Nicox?
El ratio de efectivo a ventas de Nicox es 39.93
¿Cuál es la moneda de reporte de Nicox?
Nicox presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Nicox?
El último ingresos anual de Nicox es EUR 7.14M
¿Cuál es el último beneficio anual de Nicox?
El último beneficio anual de Nicox es EUR -20.88M
¿Cuál es la dirección registrada de Nicox?
La dirección registrada de Nicox es SUNDESK SOPHIA ANTIPOLIS ,EMERALD SQUARE, B��TIMENT C, RUE EVARISTE GALOIS, BIOT, ANTIBES, ALPES-MARITIMES, 06410
¿Cuál es la dirección del sitio web de Nicox?
La dirección del sitio web de Nicox es www.nicox.com
¿En qué sector industrial opera Nicox?
Nicox opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
DRVDSDrone Volt
0.0039 €
(3,800.00%)
774.48k
GTRDSGroupe Tera DS
0.0585 €
(800.00%)
3.27k
ALCYBCybergun
0.0002 €
(100.00%)
3.98M
DMSBSDiagnostic Medical Systems
0.0075 €
(87.50%)
129.59k
NICBSNicox SA
0.0265 €
(50.57%)
979
MLSMLSmalto
0.014 €
(-33.33%)
1.62k
ALVERVergnet
0.0015 €
(-21.05%)
97.17M
MLIDSIds
0.364 €
(-19.11%)
1.12k
MCPGrupo Media Capital Sgps Sa
1.62 €
(-19.00%)
3
ALBOOBOOSTHEAT
0.063 €
(-15.78%)
70.91k
ATOAtos SE
0.002 €
(-4.76%)
2.53B
ALVERVergnet
0.0015 €
(-21.05%)
97.17M
BCPBanco Comercial Portugues SA
0.4988 €
(0.79%)
69.25M
EDPEDP SA
3.149 €
(1.22%)
13.56M
VIVVivendi SE
2.546 €
(-1.01%)
8.93M
Chartmaster Chartmaster 2 minutos hace
I struck it rich in 2021, almost 2mill$ cap gains, we just need more participation this year!
AXXA
winstocksnew winstocksnew 2 minutos hace
What will make the stock price rise? According to Rite: In short, our answer to your question is as follows: (i) first, RITE will need to be foundationally clean and stable; (ii) next RITE will need to acquire a base of assets; (iii) then RITE will need to obtain working capital to develop those ass
RITE
Bobbar Bobbar 2 minutos hace
Nope!
We need alex to finally give us an idea of whats happening

Someones loading great but i bet its just to time when they think alex will speak.
Not insiders loading
UATG
mike_dotcom mike_dotcom 3 minutos hace
Yep, I'm an idiot for buying and holding this dogschitt of a stock. I think I'm going to sign up to lend out my shares so I can at least make a LITTLE.
AVXL
marylandstockguy marylandstockguy 3 minutos hace
We got slapped upside the head! Now we know for certain, I think, that this is big dilution. What else could it be at this point? Dang it, I'm holding to the bitter end too. I hope they don't dilute the S out of this and then reverse split, but not getting a good feeling.
GTCH
kenjiroo kenjiroo 3 minutos hace
Like I said … thank me later when you finaly admit … you all live in a VuME blur !! Aint never gonna happen
TPTW
rollingrock rollingrock 3 minutos hace
The confirmation hearings confirms how stupid the dems
really are! Have you guys been watching any of them? It's fun watching Trumps picks
destroy them!
getthem1 getthem1 3 minutos hace
I have been listening to you comets on GNCP. here is the question that many here like to hear, if you don't like or don't have any share why u still here bashing ????? my best bet you are here for revenge or some thing have to do with you and ken I'm here not moving tell the end what ever you sa
GNCP
$ubmachine $ubmachine 3 minutos hace
Smart analysis - thank you!
GoodGuyBill GoodGuyBill 3 minutos hace
eyeroll...🙄
NWBO
sunspotter sunspotter 3 minutos hace
"rather have Chazzy respond, he always positive."

And look where that positivity landed you all.

He makes the same positive noises about VPLM, another wannabe patent troll which will soon follow HDVY down the toilet.
HDVY VPLM
FLA FLA 4 minutos hace
$SBES .0004 ^300%
SBES
Doc logic Doc logic 4 minutos hace
dstock07734,

Yes, I am aware of UPENN and their connection to DCVax and also being progenitors of the CAR-T technology that created a massive cytokine storm in a little girl that was attended to quickly and was then cured of her blood born cancer years ago. Novartis built out a large
NWBO
zooey zooey 4 minutos hace
So what are you doing here? You see something?
GMPR
boi568 boi568 4 minutos hace
I suspect the governments, being aware of the high MAA approval rate, will commonly enter into early discussions to move forward the availability of new drugs to their populations upon an approval.
AVXL
FLA FLA 4 minutos hace
$SBES .0004 ^300%
SBES
Zorax Zorax 4 minutos hace
Oops, there goes another mush x spacecraft....

https://www.cnn.com/science/live-news/starship-test-flight-7-launch-spacex

They should all follow her lead.

https://www.cnn.com/2025/01/14/politics/michelle-obama-trump-inauguration/index.html?iid=cnn_buildCo
richme richme 4 minutos hace
Corruption is everywhere and not just with A.I. I got scammed on computer repair starting yesterday and still on going. A company employee identified as Microsoft technician. Summary: it was not Microsoft.
MONI
StayHumble StayHumble 4 minutos hace
per11th CircuitLaw $HCMC original💹infringement Complaints Valid💹


We now turn to $HCMCs amended complaint, which presents an even stronger case in favor of $HCMC.
https://img.wattpad.com/3063c9cd99bde22340df84491c00af9aafb107a5/68747470733a2f2f73332e616
HCMC HCMCS PM
stockinspector stockinspector 5 minutos hace
Well Squirt, since you asked nicely, who do you think is
on the short side of a trade here on the OTC?
WDLF
STOCKMONSTER STOCKMONSTER 5 minutos hace
WHEN TRUMP DISMATLES THE GREEN NEW SCAM: THIS WILL TANK THE CULT EV MOVEMNT. TESLA TARGET RANGE IS NOW 200 BUCKS!!!!!!!!!!!!!!!!!!!!!!!!!!! CHINA WILL TAKE OVER BECAUSE THEY CAN MAKE 15K PER EV CAR!!!!!!!!!!!!!!!!!!!!!!!!!!!!! SORRY FOLKS - IT'S OVER!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! AND DON'T FORGET
TSLA
BottomBounce BottomBounce 5 minutos hace
Blacksky Technology $BKSY Total Debt (mrq) $105.79M Book Value Per Share (mrq) $3.62
BKSY
BottomBounce BottomBounce 5 minutos hace
Blacksky Technology $BKSY Total Debt (mrq) $105.79M Book Value Per Share (mrq) $3.62
BKSY

Su Consulta Reciente

Delayed Upgrade Clock